Article Text

Download PDFPDF

CPC-124 Rivaroxaban or Conventional Thromboprophylaxis After Major Orthopaedic Surgery in Routine Practise: Influence of Co-Medications on Outcomes in the XAMOS Study
  1. R Kreutz1,
  2. S Haas2,
  3. G Holberg3,
  4. MR Lassen4,
  5. LG Mantovani5,
  6. A Schmidt3,
  7. AGG Turpie6
  1. 1Charité, Department of Clinical Pharmacology and Toxicology, Berlin, Germany
  2. 2Institute for Experimental Oncology and Therapy Research, Technical University of Munich, Munich, Germany
  3. 3Bayer Healthcare AG, GMA, Berlin, Germany
  4. 4Glostrup Hospital University of Copenhagen, Clinical Trial Unit, Copenhagen, Denmark
  5. 5Federico II University of Naples, CIRFF Center of Pharmacoeconomics, Naples, Italy
  6. 6Hamilton Health Services, Department of Medicine, Hamilton Ontario, Canada


Background Rivaroxaban, a direct Factor Xa inhibitor, has been shown to be more effective in preventing venous thromboembolism than enoxaparin regimens, with a similar safety profile, in patients undergoing hip or knee arthroplasty (the phase III RECORD studies). Rivaroxaban is approved for this indication worldwide.

Purpose To examine the effectiveness and safety of rivaroxaban for thromboprophylaxis in routine clinical practise and the impact of selected co-medication use on outcomes.

Materials and Methods XAMOS was a phase IV, non-interventional, open-label cohort study in patients undergoing major orthopaedic surgery in daily clinical practise. The choice of rivaroxaban or standard of care (SOC) for VTE prophylaxis was at the discretion of the attending physicians. All adverse events, including symptomatic thromboembolic and bleeding events, and pre-trial and concomitant use of medicines were reported.

Results XAMOS enrolled 17,701 patients; the safety population included 17,413 patients, of whom 8778 received rivaroxaban and 8635 received SOC (81.7% low molecular weight heparin). Baseline patient demographics and use of cytochrome P450 (CYP) 3A4 inhibitors or inducers and platelet aggregation inhibitors (PAIs) before surgery were similar between groups; these drugs were used less frequently after surgery. There was a significant reduction in the incidence of symptomatic thromboembolic events in the rivaroxaban group compared with the SOC group, with numerically but not statistically higher incidence of major bleeding events. Concomitant use of PAIs was associated with higher incidences of symptomatic thromboembolic and any bleeding events compared with non-use in both the rivaroxaban and the SOC groups (Table).

Conclusions XAMOS confirmed the results of the RECORD studies. CYP3A4 inhibitors or inducers and PAIs were used less frequently after surgery compared with before surgery. The benefit–risk profile of rivaroxaban compared with SOC was maintained in routine clinical practise in patients undergoing major orthopaedic surgery, including patients with concomitant use of PAIs.

Abstract CPC-124 Table 1

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.